IMA Wealth Inc. Sells 836 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

IMA Wealth Inc. trimmed its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 3.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 24,681 shares of the company’s stock after selling 836 shares during the quarter. IMA Wealth Inc.’s holdings in CRISPR Therapeutics were worth $1,545,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Signaturefd LLC lifted its holdings in shares of CRISPR Therapeutics by 12.5% during the 3rd quarter. Signaturefd LLC now owns 2,124 shares of the company’s stock valued at $96,000 after buying an additional 236 shares during the period. Itau Unibanco Holding S.A. lifted its holdings in shares of CRISPR Therapeutics by 10.8% during the 3rd quarter. Itau Unibanco Holding S.A. now owns 2,521 shares of the company’s stock valued at $114,000 after buying an additional 245 shares during the period. Spire Wealth Management lifted its holdings in shares of CRISPR Therapeutics by 32.7% during the 3rd quarter. Spire Wealth Management now owns 1,052 shares of the company’s stock valued at $48,000 after buying an additional 259 shares during the period. CWM LLC lifted its holdings in shares of CRISPR Therapeutics by 80.7% during the 3rd quarter. CWM LLC now owns 582 shares of the company’s stock valued at $26,000 after buying an additional 260 shares during the period. Finally, WealthPlan Investment Management LLC raised its holdings in CRISPR Therapeutics by 3.1% in the 4th quarter. WealthPlan Investment Management LLC now owns 9,663 shares of the company’s stock worth $605,000 after purchasing an additional 288 shares during the period. 69.20% of the stock is owned by institutional investors.

Insider Activity

In related news, CEO Samarth Kulkarni sold 20,000 shares of CRISPR Therapeutics stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $80.36, for a total value of $1,607,200.00. Following the completion of the transaction, the chief executive officer now owns 187,377 shares in the company, valued at $15,057,615.72. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other CRISPR Therapeutics news, CFO Raju Prasad sold 3,524 shares of the business’s stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $72.69, for a total transaction of $256,159.56. Following the completion of the transaction, the chief financial officer now owns 6,476 shares in the company, valued at $470,740.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Samarth Kulkarni sold 20,000 shares of the business’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $80.36, for a total value of $1,607,200.00. Following the transaction, the chief executive officer now owns 187,377 shares of the company’s stock, valued at approximately $15,057,615.72. The disclosure for this sale can be found here. Insiders sold a total of 133,992 shares of company stock worth $9,157,835 over the last 90 days. Corporate insiders own 4.10% of the company’s stock.

Wall Street Analyst Weigh In

CRSP has been the topic of a number of recent research reports. Wells Fargo & Company raised their target price on CRISPR Therapeutics from $55.00 to $70.00 and gave the stock an “equal weight” rating in a report on Thursday, February 22nd. Needham & Company LLC reaffirmed a “buy” rating and issued a $90.00 target price on shares of CRISPR Therapeutics in a report on Thursday, April 11th. Citigroup raised their target price on CRISPR Therapeutics from $88.00 to $89.00 and gave the stock a “buy” rating in a report on Thursday, April 18th. Chardan Capital raised their target price on CRISPR Therapeutics from $110.00 to $112.00 and gave the stock a “buy” rating in a report on Thursday, February 22nd. Finally, Royal Bank of Canada raised their target price on CRISPR Therapeutics from $57.00 to $66.00 and gave the stock a “sector perform” rating in a report on Thursday, February 22nd. Three analysts have rated the stock with a sell rating, six have assigned a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, CRISPR Therapeutics presently has a consensus rating of “Hold” and an average price target of $76.29.

CRISPR Therapeutics Trading Up 0.3 %

Shares of CRISPR Therapeutics stock traded up $0.18 during trading on Friday, reaching $53.91. 1,353,533 shares of the stock traded hands, compared to its average volume of 1,233,330. The business has a fifty day simple moving average of $70.57 and a two-hundred day simple moving average of $63.81. CRISPR Therapeutics AG has a 52-week low of $37.55 and a 52-week high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Wednesday, February 21st. The company reported $1.10 earnings per share for the quarter, beating analysts’ consensus estimates of $0.15 by $0.95. The firm had revenue of $201.20 million for the quarter, compared to analysts’ expectations of $148.72 million. The company’s revenue for the quarter was up 3253.3% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.41) EPS. Equities research analysts anticipate that CRISPR Therapeutics AG will post -6.24 EPS for the current fiscal year.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.